COLLABORATION AGREEMENTCollaboration Agreement • February 8th, 2001 • Seattle Genetics Inc /Wa • Services-commercial physical & biological research • New York
THIS COLLABORATION AGREEMENT ("Agreement") is made and entered into effective as of February 2, 2001 (the "Effective Date"), by and between SEATTLE GENETICS, INC., having principal offices at 22215 26th Avenue S.E., Suite 3000, Bothell, WA 98021 ("Seattle Genetics") and MEDAREX, INC., having principal offices at 707 State Road, Suite 206, Princeton, New Jersey 08540-1437, on behalf of itself and its wholly owned subsidiary, GENPHARM INTERNATIONAL, INC., with principal offices at 2350 Qume Drive, San Jose, California 95131 (collectively, "Medarex"). Seattle Genetics and Medarex each may be referred to herein individually as a "Party," or collectively as the "Parties."
SEATTLE GENETICS, INC. COMMON STOCK PURCHASE AGREEMENT Dated as of February 2, 2001Common Stock Purchase Agreement • February 8th, 2001 • Seattle Genetics Inc /Wa • Services-commercial physical & biological research • Washington
This Common Stock Purchase Agreement (this "Agreement") is made as of February 2, 2001 between Seattle Genetics, Inc., a Delaware corporation with an office at 22215 26th Avenue SE, Suite 3000, Bothell, WA 98021(the "Company"), and Medarex, Inc., a Delaware corporation with an office at 707 State Road, Suite 206, Princeton, NJ 08540-1437 (the "Purchaser").
SEATTLE GENETICS, INC. [ ] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • February 8th, 2001 • Seattle Genetics Inc /Wa • Services-commercial physical & biological research • New York
Seattle Genetics, Inc. a Delaware corporation (the "Company"), proposes to issue and sell to the several Underwriters listed in Schedule I hereto (the "Underwriters"), for whom you are acting as representatives (the "Representatives"), an aggregate of [ ] shares (the "Underwritten Shares") of Common Stock, par value $0.001 per share, of the Company (the "Common Stock"). In addition, for the sole purpose of covering over-allotments in connection with the sale of the Underwritten Shares, the Company proposes to issue and sell to the Underwriters, at the option of the Underwriters, up to an additional [ ] shares (the "Option Shares") of Common Stock. The Underwritten Shares and the Option Shares are herein referred to as the "Shares."
